Skip to Main Content

Vertex Pharmaceuticals’ (VRTX) latest cystic fibrosis drug — the Boston biotech’s third product to reach the market — is off to a strong commercial start.

Sales of the new Vertex drug, marketed under the brand name Symdeko, totaled $34 million in the first quarter, the company said Thursday. The FDA approved Symdeko in the middle of February.


With the Symdeko contribution, Vertex reported total cystic fibrosis drug sales of $638 million in the quarter, a 33 percent increase from the same period one year ago and ahead of Wall Street consensus expectations.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!